HIMS Stock Risk & Deep Value Analysis
Hims & Hers Health Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About HIMS Stock
We analyzed Hims & Hers Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HIMS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
HIMS Risk Analysis & Red Flags
What Could Go Wrong
The FDA could impose stricter regulations or outright ban the compounding of GLP-1 drugs for weight loss, which would severely cripple Hims & Hers' fastest-growing segment and significantly impact its revenue growth projections and investor confidence. This is compounded by the financial and reputational damage from ongoing data breach lawsuits, which could lead to substantial liabilities.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Two federal data breach class-action lawsuits alleging failure to secure patient data (Feb-Apr 2026).
- ⚠
FDA's proposed curbs on compounded GLP-1 weight-loss drugs directly threaten its fastest-growing business, causing a 6.7% stock drop.
- ⚠
Multiple analyst price target reductions, with some significant cuts (e.g., from $44 to $24), leading to a 'Hold' consensus.
- ⚠
Continued insider selling of 204,857 shares worth $5.29 million over the last three months.
Upcoming Risk Events
- 📅
Adverse rulings or significant penalties from data breach lawsuits
- 📅
Stricter FDA regulations or ban on compounded GLP-1s
- 📅
Q1 2026 earnings miss and/or reduced FY26 guidance
- 📅
Increased competitive intensity from Amazon Pharmacy or large pharma
When to Reconsider
- 🚪
Exit if Q1 2026 earnings significantly miss revenue/EPS consensus and FY2026 guidance is materially lowered.
- 🚪
Sell if the FDA issues a definitive ban or highly restrictive regulations on compounded GLP-1s for weight loss.
- 🚪
Sell if the stock price consistently breaks below the $20 support level with high volume.
Unlock HIMS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Hims & Hers Health Inc (HIMS) Do?
Market Cap
$6.24B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,637
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. The company also provides Labs which measures key markers over time and provides doctor-developed action plans. Hims & Hers Health, Inc. is based in San Francisco, California.
Visit Hims & Hers Health Inc WebsiteInvestment Thesis
Hims & Hers is a high-growth direct-to-consumer telehealth platform expanding into high-demand chronic care markets, most notably GLP-1s for weight loss. While its scalable model and growing subscriber base offer significant long-term potential, the immediate investment is overshadowed by material regulatory risks impacting its core growth driver and new legal challenges from data breaches. Investment is speculative and requires close monitoring of these significant headwinds.
Is HIMS Stock Undervalued?
Unlock the full AI analysis for HIMS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HIMS Price Targets & Strategy
12-Month Target
$33.00
Bull Case
$42.00
Bear Case
$22.00
Valuation Basis
Based on 3.0x forward P/S applied to an estimated FY26 revenue of $2.7B.
Entry Strategy
Consider dollar-cost averaging in the $25-$28 range, which is near current levels but below recent highs, awaiting Q1 2026 earnings for clearer guidance.
Exit Strategy
Consider profit-taking 25% at $38.00 and another 25% at $42.00; implement a stop-loss at $22.00 if regulatory or legal headwinds intensify.
Portfolio Allocation
3-5% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is HIMS Financially Healthy?
Valuation
P/E Ratio
48.64
Profitability
Gross Margin
73.84%
Operating Margin
4.50%
Net Margin
5.47%
Return on Equity
22.99%
Revenue Growth
59.00%
EPS
$0.51
Balance Sheet
Current Ratio
1.90
Quick Ratio
1.61
Debt/Equity
1.80
Cash Flow
EBITDA
$160.10M
Other
Beta (Volatility)
2.49
Does HIMS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
3 Identified
The strong Hims & Hers brand and increasing customer base create some stickiness and trust, generating mild switching costs and network effects. However, the relatively low barrier to entry for D2C telehealth, intense competition, and high regulatory sensitivity, particularly around its fastest-growing GLP-1 segment, make this moat vulnerable. Data breaches further erode trust, a critical component of brand power.
Moat Erosion Risks
- •Intensified competition from tech giants (e.g., Amazon Pharmacy) and traditional healthcare players.
- •Adverse regulatory changes that restrict key product offerings or increase operational costs.
- •Data privacy breaches that severely damage brand reputation and consumer trust.
- •Commoditization of telehealth services leading to price wars and margin compression.
HIMS Competitive Moat Analysis
Sign up to see competitive advantages
HIMS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-to-Bearish, due to recent negative news regarding data breaches and FDA regulatory pressures impacting growth prospects.
Institutional Sentiment
Neutral-to-Negative, reflected by the 'Hold' consensus rating and several analyst price target downgrades since April 8, 2026.
Insider Activity (Form 4)
CFO Oluyemi Okupe sold 19,645 shares at $29.96 avg ($588,500 value) on April 20, 2026, under Rule 10b5-1 plan. Other unnamed insiders sold 4,651 shares ($70,742) on Feb 27, 2026, and 4,812 shares ($118,808) on March 17, 2026. Total insider selling of $5.29M over the last three months.
Options Flow
Normal options activity; no specific unusual activity reported.
Earnings Intelligence
Next Earnings
2026-05-11
Surprise Probability
Medium
Historical Earnings Pattern
Historically, growth stocks like HIMS tend to exhibit significant volatility around earnings, rallying strongly on beats with positive guidance and selling off on misses or cautious outlooks.
Key Metrics to Watch
Competitive Position
Top Competitor
TELADOC
Market Share Trend
Gaining ground with 2.5 million subscribers, representing 13% YoY growth in 2025.
Valuation vs Peers
Trading at a premium to many established telehealth peers on TTM P/E (53.65), justified by its higher growth rate, but the premium may contract with increased regulatory uncertainty and competitive threats.
Competitive Advantages
- •Strong direct-to-consumer brand recognition ('Hims' and 'Hers').
- •User-friendly and accessible digital telehealth platform.
- •Broad portfolio of conditions addressed, including high-demand areas like GLP-1s, mental health, and sexual health.
- •Positive cash flow generation providing financial flexibility.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive HIMS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 11, 2026)
- •FDA updates or clarifications on compounded GLP-1 drug regulations
- •Developments in data breach class-action lawsuits
Medium-Term (6-18 months)
- •Expansion of branded GLP-1 partnerships beyond Novo Nordisk
- •Successful integration of new chronic care verticals
- •Resolution or favorable settlement of data breach lawsuits
Long-Term (18+ months)
- •Achieving market leadership in specific D2C telehealth segments (e.g., chronic care, mental health)
- •Scalable profitability through subscriber growth and margin expansion
- •Global market expansion
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for HIMS?
- ✓
Sustained acceleration in subscriber growth and ARPU, especially in new offerings.
- ✓
Positive resolution or containment of data breach lawsuits and no further regulatory crackdowns on GLP-1s.
- ✓
Clear signs of margin expansion and increasing free cash flow despite competitive and regulatory pressures.
Bull Case Analysis
See what could go right with Premium
Competing with HIMS
See how Hims & Hers Health Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Hims & Hers Health Inc HIMS | $6.2B | 5.5 | 48.6 | $2.3B | 5.5% | 59.0% | |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
Teladoc Health Inc TDOC | — | 5.9 | — | — | — | — | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Hims & Hers Health Inc Makes Money
Hims & Hers operates a direct-to-consumer telehealth platform, connecting individuals with licensed healthcare providers for consultations, diagnosis, and prescription fulfillment across various health categories like sexual health, dermatology, mental health, and weight management. The company generates revenue primarily through a subscription-based model, offering convenience, discretion, and access to personalized care and medications, including compounded and branded GLP-1 drugs, delivered directly to the customer's home.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Hims & Hers Health Inc (HIMS)?
As of May 4, 2026, Hims & Hers Health Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Hims & Hers Health Inc?
Hims & Hers Health Inc's market capitalization is approximately $6.2B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Hims & Hers Health Inc use?
HIMS is the ticker symbol for Hims & Hers Health Inc. The company trades on the NYQ.
What is the risk level for HIMS stock?
Our analysis rates Hims & Hers Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of HIMS?
Hims & Hers Health Inc currently has a price-to-earnings (P/E) ratio of 48.6. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Hims & Hers Health Inc's revenue growing?
Hims & Hers Health Inc has reported revenue growth of 59.0%. The company is showing strong top-line momentum.
Is HIMS stock profitable?
Hims & Hers Health Inc has a profit margin of 5.5%. The company is profitable but margins are modest.
How often is the HIMS DVR analysis updated?
Our AI-powered analysis of Hims & Hers Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HIMS (Hims & Hers Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.